Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Global Industry Size, Segments, Share and Growth Factor Analysis Research Report 2026
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market | Top 10 Key Players, Demand, Revenue, Growth Factors by Types, Trends, Porters Five Force Analysis and Forecast till -2026
The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.
Request a Sample Copy of the Global Alpha-1 antitrypsin deficiency Augmentation Therapy Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/aatd-augmentation-therapy-market-100169
The Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market has been supported by late FDA endorsement for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2026.
KEY PLAYERS COVERED
Some of the major companies that are present in the Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy are Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.
Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Therapy Market are;
- Grifols S.A.
- CSL Limited
- Kamada Ltd.
- Takeda Pharmaceutical Company Limited
- Abeona Therapeutics Inc., and other players.
Highlights of the Report
- In-depth analysis of various insights, namely, Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market trends, growth drivers, opportunities, and other related challenges.
- Comprehensive details of key market players, their core competencies, and market shares.
- The potency of suppliers and buyers to make better business decisions.
- Lists out the market size in terms of volume.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/aatd-augmentation-therapy-market-100169
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Segmentation:
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
By Route of Administration
By Drug Class
- Alpha-1 proteinase inhibitor
New Biological Approval for Prolastin C to Enable Growth of Global Market
In September 2017, Grifols received biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C. The inclusion of this liquid may enable the launch of an additional alternative to the existing therapy. Clinical trials and proven efficacy have favored the approval for this product. With the latest addition to its product portfolio, Grifols will increase its stronghold in the global AATD augmentation therapy market.
KEY QUESTIONS ANSWERED:
What is the market size and growth rate of the global and regional market by various segments?
What is the market size and growth rate of the market for selective countries?
Which region or sub-segment is expected to drive the market in the forecast period?
What Factors are estimated to drive and restrain the market growth?
What are the key technological and market trends shaping the market?
What are the key opportunities in the market?
What are the key companies operating in the market?
More Trending Topics From Fortune Business [email protected]
Immunoglobulin Market Size, Growth, Share and Forecast 2025
Cardiac Pacemaker Market Size, Share and Growth Forecast 2026
Antipsychotic Drugs Market Size, Share | Global Report 2026
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: [email protected]
Website:Fortune Business Insights
Follow us on:
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Global Industry Size, Segments, Share and Growth Factor Analysis Research Report 2026